We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Shire Drugs Are Next Targets Of Hedge Fund's AIA Reviews

Law360, New York (April 2, 2015, 4:43 PM EDT) -- An organization tied to hedge fund manager Kyle Bass, whose strategy of challenging drug patents in America Invents Act inter partes reviews has recently made headlines, added two Shire PLC drugs to its list of targets in new petitions filed Wednesday.

The Coalition for Affordable Drugs, a wholly owned subsidiary of Bass' Hayman Credes Master Fund LP, filed petitions challenging patents covering Shire's drugs Lialda, which is used to treat ulcerative colitis, and Gattex, which is used to treat short bowel syndrome.

Shire said in a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.